2023 Survey: Automation Is Ubiquitous for Orphan and Specialty Drug Commercialization
87% of Biopharma Respondents Use AI/ML for Post-Market Activities, But Key Missed Opportunities...
87% of Biopharma Respondents Use AI/ML for Post-Market Activities, But Key Missed Opportunities...
By: Dan Fisher, Principal, IPM.ai
Ganesh Rajaratnam, Senior Director of Commercial Operations,...
By: Dan Fisher, Principal, IPM.ai
Allison Rhee of MM&M reports on IPM.ai's answer to patient...
By: Dan Fisher, Principal, IPM.ai
Specialty Physician Identification: Your Best Targets Could Be...
By: Dan Fisher, Principal, IPM.ai
By: Dan Fisher, Principal, IPM.ai
In anticipation of their upcoming conference presentation at ...
Driving Optimal Outcomes through the Use of Artificial Intelligence and Real World Data